parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.08 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in lymphatic endothelial cells	0.75
chemistry Open Targets	hard to drug	0.40
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	3 Parkinson's papers of 323	0.82
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 3329

receipt 3338: NR2F1 in dopamine neurons, braak

power: full sample -0.41 (p 0.087, n 18), 95% CI -0.74 to +0.07. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.41 (p 0.087, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.46 (p 0.054, n 18). could be the mix.
skeptic: leave-one-out range -0.51 to -0.34, sign flips 0; without severely affected donors -0.41 (p 0.087, n 18). robust.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NR2F1 in dopamine neurons.

case closed: nothing better to follow up.

receipt 3337: NR2F1 in astrocytes, braak

power: full sample -0.08 (p 0.767, n 18), 95% CI -0.52 to +0.41. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.06 (p 0.800, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.02 (p 0.942, n 18). could be the mix.
skeptic: leave-one-out range -0.22 to +0.05, sign flips 2; without severely affected donors -0.08 (p 0.767, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for NR2F1 in astrocytes.

case closed: nothing better to follow up.

loading the receipts